NCT02256189View on ClinicalTrials.gov

Sitagliptin and Glucagon Counterregulation

PHASE4CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

April 30, 2015

Primary Completion Date

June 30, 2017

Study Completion Date

June 30, 2017

Conditions
Type 2 Diabetes
Interventions
DRUG

Sitagliptin

Sitagliptin 100 mg daily

DRUG

Placebo

Placebo one tablet daily

Trial Locations (1)

20502

Skane University Hospital Malmö, Malmo

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Lund University

OTHER

NCT02256189 - Sitagliptin and Glucagon Counterregulation | Biotech Hunter | Biotech Hunter